Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo's 'Inversion' Of Flonase Trademark Cuts Too Close For Glaxo's Market Share Comfort

This article was originally published in The Tan Sheet

Executive Summary

Glaxo says it distributed more than $330m in Flonase Allergy Relief in 2015, its first year available as the second-in-category corticosteroid nasal spray, but argues that Nasoflow, Perrigo's brand for a generic equivalent, unfairly will encroach on its sales and market share.

Advertisement

Related Content

Bayer Fortifies Branding In OTC Naproxen Market With Win In Trademark Litigation
Perrigo Nutritional Portfolio Grows As Supplement Business Sale Proceeds
Oxytrol For Women Exclusivity Ends Not With Competition, But Label Warning Change
Flonase Allergy Relief Exclusivity Sliced Up By Label Carve-Out
Adulturated red yeast rice

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS108208

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel